JP2020533002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533002A5 JP2020533002A5 JP2020514677A JP2020514677A JP2020533002A5 JP 2020533002 A5 JP2020533002 A5 JP 2020533002A5 JP 2020514677 A JP2020514677 A JP 2020514677A JP 2020514677 A JP2020514677 A JP 2020514677A JP 2020533002 A5 JP2020533002 A5 JP 2020533002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- optionally
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 229910052705 radium Inorganic materials 0.000 claims 6
- 230000002285 radioactive effect Effects 0.000 claims 5
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 4
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 4
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims 4
- 229910052797 bismuth Inorganic materials 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 229910052687 Fermium Inorganic materials 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 229910052776 Thorium Inorganic materials 0.000 claims 2
- 229910052767 actinium Inorganic materials 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558230P | 2017-09-13 | 2017-09-13 | |
| US62/558,230 | 2017-09-13 | ||
| PCT/US2018/050955 WO2019055706A1 (en) | 2017-09-13 | 2018-09-13 | ANTI-MELANIN ANTIBODIES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533002A JP2020533002A (ja) | 2020-11-19 |
| JP2020533002A5 true JP2020533002A5 (enExample) | 2021-10-21 |
Family
ID=65723127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514677A Pending JP2020533002A (ja) | 2017-09-13 | 2018-09-13 | メラニン抗体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11760791B2 (enExample) |
| EP (1) | EP3681541A4 (enExample) |
| JP (1) | JP2020533002A (enExample) |
| KR (1) | KR20200044968A (enExample) |
| CN (1) | CN111465414B (enExample) |
| AU (1) | AU2018331430A1 (enExample) |
| CA (1) | CA3074715A1 (enExample) |
| IL (1) | IL273048A (enExample) |
| WO (1) | WO2019055706A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021010799A2 (pt) * | 2018-12-03 | 2021-08-24 | Fusion Pharmaceuticals Inc. | Terapia combinada com radioimunoconjugados e inibidor do ponto de verificação |
| KR20220070116A (ko) | 2020-11-20 | 2022-05-30 | 주식회사 하울바이오 | 멜라닌 생성을 억제하는 항-티로시나아제 b8 항체 및 이의 용도 |
| KR20220112074A (ko) | 2021-02-03 | 2022-08-10 | 주식회사 세바바이오텍 | 멜라닌 생성 억제 효능을 갖는 항체가 함유된 비드 및 이의 용도 |
| CN119735674A (zh) * | 2024-12-06 | 2025-04-01 | 合肥综合性国家科学中心大健康研究院 | 抗vmat2的抗体或其抗原结合片段及其组合物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402385B2 (en) * | 2003-02-11 | 2008-07-22 | Albert Einstein College Of Medicine Of Yeshiva University | Radiolabeled antibodies for treatment of tumors |
| US20060039858A1 (en) | 2003-02-11 | 2006-02-23 | Ekaterina Dadachova | Radiolabeled antibodies and peptides for treatment of tumors |
| US20110300067A1 (en) | 2008-09-09 | 2011-12-08 | Ekaterina Dadachova | Methods for increasing efficacy of radioimmunotherapy of melanoma |
| EA029793B1 (ru) | 2010-08-23 | 2018-05-31 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Антитела к ох40 и способы их применения |
| DK2794658T3 (en) | 2011-12-19 | 2017-06-19 | Synimmune Gmbh | BISPECIFIC ANTIBODY MOLECULE |
| MX389663B (es) * | 2014-10-14 | 2025-03-20 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. |
-
2018
- 2018-09-13 JP JP2020514677A patent/JP2020533002A/ja active Pending
- 2018-09-13 CA CA3074715A patent/CA3074715A1/en active Pending
- 2018-09-13 WO PCT/US2018/050955 patent/WO2019055706A1/en not_active Ceased
- 2018-09-13 EP EP18856150.0A patent/EP3681541A4/en not_active Withdrawn
- 2018-09-13 AU AU2018331430A patent/AU2018331430A1/en not_active Abandoned
- 2018-09-13 US US16/646,994 patent/US11760791B2/en active Active
- 2018-09-13 CN CN201880073136.1A patent/CN111465414B/zh not_active Expired - Fee Related
- 2018-09-13 KR KR1020207010372A patent/KR20200044968A/ko not_active Ceased
-
2020
- 2020-03-04 IL IL273048A patent/IL273048A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535670A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2016500655A5 (enExample) | ||
| JP2019524693A5 (enExample) | ||
| JP2018508483A5 (enExample) | ||
| IL253462B (en) | Treatment of cancer with anti-lap monoclonal antibodies | |
| JP2018501197A5 (enExample) | ||
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| JP2018532383A5 (enExample) | ||
| JP2011509245A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| CN106659779A (zh) | 双特异性四价抗体及其制造和使用方法 | |
| IL295295A (en) | Antibodies against fcrl5 and methods of their use | |
| JP2021508707A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| WO2016154047A3 (en) | Monoclonal antigen-binding proteins to intracellular oncogene products | |
| JP2020534830A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| JP2020533002A5 (enExample) | ||
| JP2017519501A5 (enExample) | ||
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи |